KAKKIS EMIL D
President & CEO
KAKKIS EMIL D has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Apr 20, 2026.
On the most recent filing, KAKKIS EMIL D is listed as President & CEO at Ultragenyx Pharmaceutical Inc. Inside the rolling window, KAKKIS EMIL D reported no open-market purchases and 1 open-market sale totaling $1.2M in RARE.
Companies traded
Other insiders at RARE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.2M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has KAKKIS EMIL D made?
KAKKIS EMIL D has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does KAKKIS EMIL D trade?
KAKKIS EMIL D has filed SEC Form 4 disclosures for 1 company, including RARE.
When was KAKKIS EMIL D's most recent SEC Form 4 filing?
KAKKIS EMIL D's most recent SEC Form 4 filing on Tracefour is dated Apr 20, 2026.
What is KAKKIS EMIL D's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, KAKKIS EMIL D is listed as President & CEO.
What is KAKKIS EMIL D's total buy and sell value in the current window?
Inside the rolling retention window, KAKKIS EMIL D bought $0 and sold $1.2M based on SEC Form 4 filings.
What was KAKKIS EMIL D's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 54,404 RARE shares on 2026-03-02, worth $1.2M, per SEC Form 4 filings.